000126505 001__ 126505
000126505 005__ 20240228140829.0
000126505 0247_ $$2doi$$a10.1002/ijc.29258
000126505 0247_ $$2pmid$$apmid:25303768
000126505 0247_ $$2ISSN$$a0020-7136
000126505 0247_ $$2ISSN$$a1097-0215
000126505 0247_ $$2altmetric$$aaltmetric:2763748
000126505 037__ $$aDKFZ-2017-02533
000126505 041__ $$aeng
000126505 082__ $$a610
000126505 1001_ $$0P:(DE-HGF)0$$aFernández-Ulibarri, Inés$$b0$$eFirst author
000126505 245__ $$aGenetic delivery of an immunoRNase by an oncolytic adenovirus enhances anticancer activity.
000126505 260__ $$aBognor Regis$$bWiley-Liss$$c2015
000126505 3367_ $$2DRIVER$$aarticle
000126505 3367_ $$2DataCite$$aOutput Types/Journal article
000126505 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1525339295_2482
000126505 3367_ $$2BibTeX$$aARTICLE
000126505 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000126505 3367_ $$00$$2EndNote$$aJournal Article
000126505 520__ $$aAntibody therapy of solid cancers is well established, but suffers from unsatisfactory tumor penetration of large immunoglobulins or from low serum retention of antibody fragments. Oncolytic viruses are in advanced clinical development showing excellent safety, but suboptimal potency due to limited virus spread within tumors. Here, by developing an immunoRNase-encoding oncolytic adenovirus, we combine viral oncolysis with intratumoral genetic delivery of a small antibody-fusion protein for targeted bystander killing of tumor cells (viro-antibody therapy). Specifically, we explore genetic delivery of a small immunoRNase consisting of an EGFR-binding scFv antibody fragment fused to the RNase Onconase (ONC(EGFR)) that induces tumor cell death by RNA degradation after cellular internalization. Onconase is a frog RNase that combines lack of immunogenicity and excellent safety in patients with high tumor killing potency due to its resistance to the human cytosolic RNase inhibitor. We show that ONC(EGFR) expression by oncolytic adenoviruses is feasible with an optimized, replication-dependent gene expression strategy. Virus-encoded ONC(EGFR) induces potent and EGFR-dependent bystander killing of tumor cells. Importantly, the ONC(EGFR)-encoding oncolytic adenovirus showed dramatically increased cytotoxicity specifically to EGFR-positive tumor cells in vitro and significantly enhanced therapeutic activity in a mouse xenograft tumor model. The latter demonstrates that ONC(EGFR) is expressed at levels sufficient to trigger tumor cell killing in vivo. The established ONC(EGFR)-encoding oncolytic adenovirus represents a novel agent for treatment of EGFR-positive tumors. This viro-antibody therapy platform can be further developed for targeted/personalized cancer therapy by exploiting antibody diversity to target further established or emerging tumor markers or combinations thereof.
000126505 536__ $$0G:(DE-HGF)POF3-316$$a316 - Infections and cancer (POF3-316)$$cPOF3-316$$fPOF III$$x0
000126505 588__ $$aDataset connected to CrossRef, PubMed,
000126505 650_7 $$2NLM Chemicals$$aAntibodies, Viral
000126505 650_7 $$2NLM Chemicals$$aAntineoplastic Agents
000126505 650_7 $$063231-63-0$$2NLM Chemicals$$aRNA
000126505 650_7 $$0EC 2.7.10.1$$2NLM Chemicals$$aEGFR protein, human
000126505 650_7 $$0EC 2.7.10.1$$2NLM Chemicals$$aReceptor, Epidermal Growth Factor
000126505 650_7 $$0EC 3.1.-$$2NLM Chemicals$$aRibonucleases
000126505 7001_ $$0P:(DE-HGF)0$$aHammer, Katharina$$b1
000126505 7001_ $$0P:(DE-He78)25866e5f0faaf24f74afbfa0b1708129$$aArndt, Michaela$$b2$$udkfz
000126505 7001_ $$0P:(DE-HGF)0$$aKaufmann, Johanna K$$b3
000126505 7001_ $$0P:(DE-HGF)0$$aDorer, Dominik$$b4
000126505 7001_ $$0P:(DE-HGF)0$$aEngelhardt, Sarah$$b5
000126505 7001_ $$aKontermann, Roland E$$b6
000126505 7001_ $$0P:(DE-He78)2e5f34f1c58eda4787a14c9dc139ca5f$$aHess, Jochen$$b7$$udkfz
000126505 7001_ $$0P:(DE-He78)69067807288b48415ceb4abc43b9ad54$$aAllgayer, Heike$$b8$$udkfz
000126505 7001_ $$0P:(DE-He78)89b4ff27ea0f9302f33c3078bf71e97e$$aKrauss, Jürgen$$b9$$udkfz
000126505 7001_ $$0P:(DE-He78)a074bc4fb40eed64043b5d34b4d6d523$$aNettelbeck, Dirk$$b10$$eLast author$$udkfz
000126505 773__ $$0PERI:(DE-600)1474822-8$$a10.1002/ijc.29258$$gVol. 136, no. 9, p. 2228 - 2240$$n9$$p2228 - 2240$$tInternational journal of cancer$$v136$$x0020-7136$$y2015
000126505 909CO $$ooai:inrepo02.dkfz.de:126505$$pVDB
000126505 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000126505 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000126505 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)25866e5f0faaf24f74afbfa0b1708129$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000126505 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000126505 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000126505 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000126505 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2e5f34f1c58eda4787a14c9dc139ca5f$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000126505 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)69067807288b48415ceb4abc43b9ad54$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000126505 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)89b4ff27ea0f9302f33c3078bf71e97e$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000126505 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a074bc4fb40eed64043b5d34b4d6d523$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000126505 9131_ $$0G:(DE-HGF)POF3-316$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vInfections and cancer$$x0
000126505 9141_ $$y2015
000126505 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000126505 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000126505 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000126505 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000126505 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J CANCER : 2015
000126505 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000126505 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000126505 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000126505 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000126505 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000126505 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000126505 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J CANCER : 2015
000126505 9201_ $$0I:(DE-He78)F110-20160331$$kF110$$lOnkolytische Adenoviren$$x0
000126505 9201_ $$0I:(DE-He78)D120-20160331$$kD120$$lAngewandte Tumor-Immunität$$x1
000126505 9201_ $$0I:(DE-He78)G405-20160331$$kG405$$lMolekulare Grundlagen von HNO-Tumoren$$x2
000126505 9201_ $$0I:(DE-He78)G360-20160331$$kG360$$lKKE Molekulare Onkologie solider Tumoren$$x3
000126505 980__ $$ajournal
000126505 980__ $$aVDB
000126505 980__ $$aI:(DE-He78)F110-20160331
000126505 980__ $$aI:(DE-He78)D120-20160331
000126505 980__ $$aI:(DE-He78)G405-20160331
000126505 980__ $$aI:(DE-He78)G360-20160331
000126505 980__ $$aUNRESTRICTED